Skip to main content
. 2019 Aug 19;13:2899–2909. doi: 10.2147/DDDT.S212500

Table 2.

Clinical trial of obinutuzumab

Trials Phase Dose (mg) No. of pts Treatment Best response
GAUGUIN I 400–1200 13 O ORR 62%
GAUGUIN II 1000 20 O ORR 30%
GALTION Ib 1000 20 O+B ORR 90%
GALTION 21 O+FC ORR 62%
GAGE II 1000 41 O ORR 49%
GAGE 2000 39 O ORR 66%
CLL11 III (stage 1) 1000 238 O+C ORR 31%
CLL11 233 R+C ORR 79%
CLL11 (stage 2) 330 R+C ORR 65%
CLL11 333 O+C ORR 78.4%

Abbreviations: O, obinutuzumab; B, bendamustine; FC, fludarabine/cyclophosphamide; R, rituximab; C, chlorambucil; ORR, overall response rate.